User Fee Goals Needed To Balance FDA Caution, Former Counsel Troy Says

The prescription drug user fee program must be preserved to prevent FDA from becoming overly cautious on drug approvals, former FDA Chief Counsel Dan Troy told the Milken Institute Global Conference in Los Angeles April 18